102775
论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
尿激酶型纤溶酶原激活剂受体对胃癌和结直肠癌患者预后的作用： 系统回顾和汇总分析
Authors Guo H, Ling C, Ma YY, Zhou LX, Zhao L
Published Date June 2015 Volume 2015:8 Pages 1503—1509
DOI http://dx.doi.org/10.2147/OTT.S80634
Received 9 January 2015, Accepted 17 April 2015, Published 19 June 2015
Approved for publication by Professor Jianmin Xu
Purpose: Although the urokinase plasminogen activator receptor (uPAR) is expressed in gastric cancer (GC) and colorectal cancer (CRC), its evaluation as a prognostic biomarker remains controversial. In this study, we performed a literature review and meta-analysis to evaluate the association of uPAR expression with the prognosis of patients with GC and CRC.
Method: The PubMed database was searched for material published in English, and data were then extracted and assessed by two reviewers independently. Correlations between uPAR expression and clinicopathological features and overall survival (OS) of patients with GC or CRC were analyzed.
Results: A total of 2,082 patients with GC and CRC from ten studies were included. The results of the meta-analysis showed that the uPAR expression rate in GC and CRC tissues was higher than that in normal tissues (odds ratio [OR] =3.385; 95% confidence interval [CI] 2.605–4.400; P =0.000). Our meta-analysis also revealed a significant association between uPAR expression and lymph node metastasis (OR =1.366; 95% CI =1.086–1.718; P =0.008) and tumor stage (OR =3.076; 95% CI =2.330–4.061; P =0.000). Furthermore, we found that high uPAR expression correlated with poor OS (OR =1.937; 95% CI =1.570–2.930; P =0.000).
Conclusion: The uPAR expression may serve as a novel disease marker in GC and CRC, as well as a therapeutic target.
Keywords: uPAR, gastric cancer, colorectal cancer, meta-analysis
Method: The PubMed database was searched for material published in English, and data were then extracted and assessed by two reviewers independently. Correlations between uPAR expression and clinicopathological features and overall survival (OS) of patients with GC or CRC were analyzed.
Results: A total of 2,082 patients with GC and CRC from ten studies were included. The results of the meta-analysis showed that the uPAR expression rate in GC and CRC tissues was higher than that in normal tissues (odds ratio [OR] =3.385; 95% confidence interval [CI] 2.605–4.400; P =0.000). Our meta-analysis also revealed a significant association between uPAR expression and lymph node metastasis (OR =1.366; 95% CI =1.086–1.718; P =0.008) and tumor stage (OR =3.076; 95% CI =2.330–4.061; P =0.000). Furthermore, we found that high uPAR expression correlated with poor OS (OR =1.937; 95% CI =1.570–2.930; P =0.000).
Conclusion: The uPAR expression may serve as a novel disease marker in GC and CRC, as well as a therapeutic target.
Keywords: uPAR, gastric cancer, colorectal cancer, meta-analysis
Download Article[PDF]
